Trial · NCT03328897
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline of the Itch Severity Score (ISS7) Score After 12 Weeks of Treatment | Omalizumab 300mg | -10.11 | Standard Error 0.430 | Score on a scale | |
| Change From Baseline of the Itch Severity Score (ISS7) Score After 12 Weeks of Treatment | Omalizumab 150mg | -9.66 | Standard Error 0.424 | Score on a scale | |
| Change From Baseline of the Itch Severity Score (ISS7) Score After 12 Weeks of Treatment | Placebo | -5.87 | Standard Error 0.604 | Score on a scale | |
| Change From Baseline of Urticaria Activity Score (UAS7) After 12 Weeks of Treatment | Omalizumab 300mg | -21.82 | Standard Error 0.895 | Score on a scale | |
| Change From Baseline of Urticaria Activity Score (UAS7) After 12 Weeks of Treatment | Omalizumab 150mg | -20.74 | Standard Error 0.882 | Score on a scale | |
| Change From Baseline of Urticaria Activity Score (UAS7) After 12 Weeks of Treatment | Placebo | -11.62 | Standard Error 1.258 | Score on a scale | |
| Change From Baseline of Number of Hives Score (NHS7) After 12 Weeks of Treatment | Omalizumab 300mg | -11.68 | Standard Error 0.492 | Score on a scale | |
| Change From Baseline of Number of Hives Score (NHS7) After 12 Weeks of Treatment | Omalizumab 150mg | -11.11 | Standard Error 0.485 | Score on a scale | |
| Change From Baseline of Number of Hives Score (NHS7) After 12 Weeks of Treatment | Placebo | -5.76 | Standard Error 0.690 | Score on a scale | |
| Percentage of Patients With UAS7≤6 at Week 12 | Omalizumab 300mg | 81 | Participants | ||
| Percentage of Patients With UAS7≤6 at Week 12 | Omalizumab 150mg | 79 | Participants | ||
| Percentage of Patients With UAS7≤6 at Week 12 | Placebo | 9 | Participants | ||
| Percentage of Complete Responders (UAS7 = 0) at Week 12 | Omalizumab 300mg | 62 | Participants | ||
| Percentage of Complete Responders (UAS7 = 0) at Week 12 | Omalizumab 150mg | 39 | Participants | ||
| Percentage of Complete Responders (UAS7 = 0) at Week 12 | Placebo | 4 | Participants | ||
| Percentage of Patients With ISS7 Minimally Important Difference (MID) at Week 12 | Omalizumab 300mg | 125 | Participants | ||
| Percentage of Patients With ISS7 Minimally Important Difference (MID) at Week 12 | Omalizumab 150mg | 125 | Participants | ||
| Percentage of Patients With ISS7 Minimally Important Difference (MID) at Week 12 | Placebo | 49 | Participants | ||
| Change From Baseline of Dermatology Life Quality Index (DLQI) Score After 12 Weeks of Treatment | Omalizumab 300mg | -10.4 | Standard Error 0.50 | Score on a scale | |
| Change From Baseline of Dermatology Life Quality Index (DLQI) Score After 12 Weeks of Treatment | Omalizumab 150mg | -9.9 | Standard Error 0.49 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03328897/results